Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.34 |
| ▸ | NOS2 | P35228 | 4/20 | 0.34 |
| ▸ | XIAP | P98170 | 2/20 | 0.30 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6751157 | 0.91 | XIAP (0.34) | CYP2D6SLC6A2SLC6A4NOS2XIAP | |
| SCHEMBL6746363 | 0.91 | CYP2D6 (0.35) | CYP2D6SLC6A2SLC6A4NOS2XIAP | |
| SCHEMBL6750088 | 0.89 | CYP2D6 (0.33) | CYP2D6SLC6A2SLC6A4NOS2XIAP | |
| SCHEMBL6750051 | 0.86 | XIAP (0.30) | XIAPBIRC2ALDH1A1 | |
| SCHEMBL6750975 | 0.83 | CYP2D6 (0.52) | CYP2D6SLC6A2SLC6A4NOS2NPSR1 | |
| SCHEMBL6842377 | 0.83 | CYP2D6 (0.52) | CYP2D6SLC6A2SLC6A4NOS2NPSR1 | |
| SCHEMBL6746343 | 0.83 | CYP2D6 (0.33) | CYP2D6SLC6A2SLC6A4NOS2ALDH1A1 | |
| SCHEMBL6750046 | 0.82 | CYP2D6 (0.37) | CYP2D6SLC6A2SLC6A4NOS2ALDH1A1 | |
| SCHEMBL4595884 | 0.81 | ALDH1A1 (0.31) | CYP2D6SLC6A2SLC6A4NOS2ALDH1A1 | |
| SCHEMBL6750103 | 0.80 | ALDH1A1 (0.38) | XIAPBIRC2SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | CYP1A1, NOS3, NOS1 | CYP2D6 48/4885SLC6A2 2580/4885SLC6A4 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.